Studies gut bacteria and muscle wasting in people on dialysis
Observes gut bacteria, inflammation and body wasting in adults on dialysis.
Plain-language title generated from the registry record
Registry title: CKD Cachexia and Gut Microbiome
Key facts
- Where
- Brussels, BelgiumSee the 2 sites
Where in Belgium
- Cliniques universitaires Saint-LucBrussels, BelgiumTaking people
- UCLouvainBrussels, BelgiumNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Université Catholique de Louvain
- Trial code
- NCT06986265
- Record updated
- 22 May 2025
- Original description
Cachexia is common in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality. Cachexia is a complex syndrome, in which inflammation and retention of uremic toxins are two main contributing factors. In this context, the role of the gut microbiome in CKD cachexia and the potential benefit of increasing the dialysis dose have been poorly explored. Here the investigators propose to study the links between cachexia and the gut microbiome, in association with inflammation and uremic toxins, in dialysis.Read full original descriptionShow less
Association of Cachexia and Gut Microbiome in Dialysis Patients : Investigation of the Interactions With Uremic Toxins and Inflammation.
Cachexia is common in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality. Cachexia is a complex syndrome, in which inflammation and retention of uremic toxins are two main contributing factors. In this context, the role of the gut microbiome in CKD cachexia and the potential benefit of increasing the dialysis dose have been poorly explored. Here the investigators propose to study the links between cachexia and the gut microbiome, in association with inflammation and uremic toxins, in dialysis.
The specific objectives are the followings:
1. Set up a prospective cohort of deeply characterized kidney failure patients treated with hemodialysis (in-center, self-care dialysis in a satellite unit and at home) and peritoneal dialysis, including evaluation of cachexia, body composition, collection of feces and blood to characterize the gut microbiota, measure serum levels of uremic toxins and inflammatory markers, with a longitudinal follow-up. 2. To compare cachectic versus non-cachectic dialysis patients in terms of gut microbiota, inflammatory markers, level of uremic toxins, muscle transcriptome, dialysis dose and modality. In a subgroup analysis, the investigators plan to compare the different techniques of dialysis (in-center vs home-hemodialysis vs peritoneal dialysis).
Inclusion: Age ≥ 18 years; Diagnosis of kidney failure (stage V); Maintenance dialysis for at least 3 months; Understanding of the trial procedures and ability to adhere to the trial protocol.
Exclusion: Bariatric surgery; Gastro-intestinal surgery, colonoscopy, or probiotics consumption in the 3 months preceding the inclusion; Drugs influencing body composition initiated ≤ 1 month : systemic corticosteroids, anabolic drugs as insulin or testosterone, post-menopausal hormone therapy, injectable contraceptives; Patients under weight loss drugs : GLP1 agonists, orlistat; Chronic inflammatory disease of the digestive tract (Crohn's disease, ulcerative colitis); Active cancer; Known endocrinological disorders potentially leading to hypo- or hypermetabolism, untreated or treated for ≤ 1 month : disorders of thyroid gland, adrenal glands; Severe nonadherence to the dialysis procedure; Life expectancy below 1 year; Pregnancy; Antibiotics consumption in the month preceding the inclusion.